Exposure‐response relationship of ramucirumab in RANGE, a randomized phase III trial in advanced urothelial carcinoma refractory to platinum therapy

AIMS: Patients with advanced urothelial carcinoma (UC) who progress after platinum‐based chemotherapy have a poor prognosis, and there is a medical need to improve current treatment options. Ramucirumab plus docetaxel significantly improved progression‐free survival but not overall survival (OS) in...

Descripción completa

Detalles Bibliográficos
Autores principales: de Wit, Ronald, Powles, Thomas, Castellano, Daniel, Necchi, Andrea, Lee, Jae‐Lyun, van der Heijden, Michiel S., Matsubara, Nobuaki, Bamias, Aristotelis, Fléchon, Aude, Sternberg, Cora N., Drakaki, Alexandra, Yu, Evan Y., Zimmermann, Annamaria H., Long, Amanda, Walgren, Richard A., Gao, Ling, Bell‐McGuinn, Katherine M., Petrylak, Daniel P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302693/
https://www.ncbi.nlm.nih.gov/pubmed/35029306
http://dx.doi.org/10.1111/bcp.15233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9302693/
https://www.ncbi.nlm.nih.gov/pubmed/35029306
http://dx.doi.org/10.1111/bcp.15233

Ejemplares similares